The Drugs.com Monthly Update Podcast

In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes. 

Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials.

Icotyde (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice.

Sotyktu (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic arthritis, addressing inflammation with a convenient dosing regimen.

Awiqli (insulin isodec): The first once-weekly basal insulin for adults with type 2 diabetes.

Chapters:

• (00:21) - Intro
• (01:00) - Wegovy HD
• (02:10) - Icotyde
• (03:12) - Sotyktu
• (03:53) - Awiqli
• (04:32) - Outro

Follow Drugs.com: